VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Cortes Discusses FLT3 Inhibitors in AML

J​orge E. Cortes, MD
Published: Thursday, Jun 22, 2017



Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 


Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x